Intravitreal injection of Ozurdex(®) implant in patients with persistent diabetic macular edema, with six-month follow-up

AIM: To evaluate the efficacy of intravitreal dexamethasone injections in diabetic macular edema (DME). METHODS: A 700 μg slow-release intravitreal dexamethasone implant (Ozurdex®) was placed in the vitreal cavity of 17 patients (19 eyes) affected with persistent DME. Best corrected visual acuity (BCVA) was assessed through Early Treatment Diabetic Retinopathy Study (ETDRS). Central macular thickness (CMT) was measured by spectral-domain optical coherence tomography. BCVA and CMT examinations were carried out at baseline (T0) and repeated after three days, one month (T1), three months (T3), four months (T4), and six months (T6) post injection. RESULTS: Dexamethasone implant induced an improvement in ETDRS at T1, T3, T4, and T6 post injection. CMT was reduced at T1, T3, and T4, while at T6, CMT values were not statistically different from baseline. No complications were observed during the follow-up. CONCLUSION: Our data suggest that dexamethasone implant is effective in reducing DME symptoms within a six-month frame

Inspiratory fraction as a marker of skeletal muscle dysfunction in patients with COPD

AbstractBackgroundAn inspiratory capacity to total lung capacity (IC/TLC) ratio of ≤25% has emerged as a better marker of mortality in chronic obstructive pulmonary disease (COPD) patients. The relationship among the IC/TLC ratio to lower extremity skeletal muscle function remains unknown.MethodsThirty-five men with moderate to severe COPD were divided into those with IC/TLC≤25% (n=16) and >25% (n=19). The subjects were tested for thigh muscle mass volume (MMT), maximal strength, power output of the lower extremities, and physical activity.ResultsTotal MMT in the IC/TLC<25% group was significantly lower (413.91±89.42cm3) (p<0.001) than in the IC/TLC>25% group (575.20±11.76cm3). In the IC/TLC≤25% group, maximal strength of the lower extremities and muscle peak power output of the lower extremities were 36–56% lower (p<0.01) than among the patients in the IC/TLC>25% group.ConclusionIC/TLC≤25% is associated with reduced maximal strength and peak power output of the lower extremities. IC/TLC≤25% may have an important clinical relevance as an index to determine peripheral muscle dysfunction

Aplicação da espectroscopia no infravermelho próximo e médio na avaliação da biomassa microbiana do solo.

A biomassa microbiana tem sido um bom indicador da qualidade do solo devido à sua importante participação nos ciclos biogeoquímicos e à sua interação com a matéria orgânica e minerais presentes no solo. O método comumente utilizado em laboratório para sua determinação é o proposto por Vance et al. (1987), que envolve processos de fumigação e extração, além etapas de preparação de amostras. Por outro lado, a espectroscopia de infravermelho tem sido proposta para a análise de solos e produtos agrícolas, em substituição aos métodos clássicos, pela economia de tempo e custo. Entretanto, a utilização da espectroscopia de infravermelho próximo (NIRS) e médio (DRIFTS) nas análises de solos depende da construção de modelos preditivos que correlacionem os dados espectroscópicos com os valores obtidos com um método de referência. Desse modo, para avaliar a aplicabilidade dessas técnicas na determinação de carbono microbiano (CMIC), nitrogênio microbiano (NMIC) e respiração basal do solo (RB), foram utilizadas amostras provenientes da Fazenda Capivara, pertencente à Embrapa Arroz e Feijão (CNPAF), em Santo Antônio de Goiás-GO, e da Fazenda Canchim, pertencente à Embrapa Pecuária Sudeste (CPPSE), em São Carlos-SP. Os dados de biomassa obtidos com o método utilizado como referência (fumigação-extração) foram correlacionados com os dados de absorbância em infravermelho pelo método PLS (Partial Least Squares), em dois subgrupos amostrais segundo a localidade (CNPAF e CPPSE), assim como em todas as amostras. Os testes de validação dos modelos de regressão construídos confirmaram que há relação quantitativa entre os espectros de infravermelho e os parâmetros de biomassa microbiana, sendo os coeficientes de regressão máximos encontrados iguais a 0,82 para CMIC; 0,76 para NMIC e 0,70 para RB.bitstream/item/64194/1/boletimdepesquisa-38.pd

Espectroscopia de infravermelho na determinação da textura do solo.

A aplicação de técnicas espectroscópicas que utilizam a radiação infravermelha (NIRS-Near Infrared Spectroscopy e DRIFTS-Diffuse Reflectance Fourier Transformed Spectroscopy ) na análise inorgânica do solo tem sido proposta desde a década de 1970, mas até os dias atuais são raros os métodos implementados rotineiramente no Brasil. Isso deve-se à dificuldade em construir modelos de calibração, por meio de métodos estatísticos multivariados, utilizando-se amostras reais de solo, de constituição complexa, que varia geograficamente e de acordo com o manejo. Por isso, os objetivos deste trabalho foram construir modelos de calibração em NIRS e DRIFTS para a quantificação das frações de argila e areia, em amostras de solos de classes diferentes - Latossolo Vermelho (predominante), Nitossolo, Argissolo Vermelho e Neossolo Quartzarênico - e avaliar qual dessas duas técnicas é mais adequada para essa finalidade, assim como a interferência do agrupamento de amostras e da seleção de variáveis espectrais na qualidade desses modelos. Para isso, valores de referência obtidos pelo método do densímetro, método largamente utilizado nos laboratórios de análise de solo, foram correlacionados com valores de absorbância em NIRS e DRIFTS pela ferramenta estatística PLS (Partial Least Squares ), obtendo-se altos coeficientes de determinação (R 2), de 0,95, 0,90 e 0,91 para argila, silte e areia, respectivamente, na validação externa. Isso confirma a aplicabilidade das técnicas espectroscópicas na análise granulométrica do solo para fins agrícolas. O agrupamento das amostras segundo a localização e a seleção de variáveis espectrais pouco influenciou na qualidade dos modelos. A técnica espectroscópica mais indicada para essa finalidade foi a DRIFT

Enrofloxacin against Escherichia coli in turkeys: Which treatment scheme is effective?

Abstract The efficacy of enrofloxacin (ENRO) was evaluated against multidrug-resistant avian pathogenic Escherichia coli correlating the minimum inhibitory concentrations (MIC) of 235 E. coli field strains with its pharmacokinetics (PK) in 50 healthy turkeys (5 groups) with a PK/pharmacodynamic approach. The treatments were as follows: a) single oral gavage and b) single subcutaneous (SC) treatment at the recommended dose of 10 mg/kg; c) single oral gavage, d) 5 d of 10-h pulsed water medication, and e) 5 d of 24-h continuous water medication at the doubled dose of 20 mg/kg. Blood samples were collected at established times over 24 h. Plasma was analyzed using a liquid chromatography tandem mass spectrometry method that was validated in house. A monocompartmental and a noncompartmental model were applied to the data to obtain the PK results. After gavage administration, the mean maximum concentration Cmax/MIC50 and area under the curve AUC0–24/MIC50 ratios were, respectively, 3.07 ± 0.62 and 7.01 ± 1.03 and 25.48 ± 3.04 and 57.2 ± 3.73 for the 10 and 20 mg/kg doses, respectively. After SC administration of 10 mg/kg, Cmax/MIC50 and AUC0–24/MIC50 ratios were 3.45 ± 0.75 and 33.96 ± 7.46, respectively. After the administration of 10-h pulsed or 24-h continuous medicated water at 20 mg/kg, lower values of Cmax/MIC50 (10-h pulsed: 3.45 ± 0.7; 24-h continuous: 3.05 ± 0.48) and AUC0–24/MIC50 (10-h pulsed: 42.42 ± 6.17; 24-h continuous: 53.32 ± 5.55) were obtained. Based on these results, the European Union-recommended dosage of 10 mg/kg seems ineffective to achieve adequate drug plasma concentrations and even the 20 mg/kg by 10 h pulsed or continuous medicated water administration did not reach completely efficacious concentrations in plasma against colibacillosis. Although the results obtained were not completely encouraging, the medicated water should preferably be provided continuously. To conclude about the efficacy of ENRO treatment against colibacillosis, target tissue concentration should be extensively considered

pharmacokinetic pharmacodynamic evaluation of the efficacy of flumequine in treating colibacillosis in turkeys

Abstract Flumequine (FLU) is used in the treatment of systemic bacterial infections in poultry, including colibacillosis, which is a common disease in turkeys. The pharmacokinetic (PK) behavior of FLU administered to 32 healthy turkeys as an oral bolus via gavage or as 10-h pulsed administration in drinking water were compared, using the authorized dose of 15 mg/kg and the double dose of 30 mg/kg. The minimum inhibitory concentrations (MIC) of 235 Escherichia coli field strains isolated from poultry were determined for pharmacodynamics (PD) to develop a PK/PD model. Blood samples were collected at established times over 24 h, and the obtained plasma was analyzed using a liquid chromatography tandem mass spectrometry method that was validated in-house. A monocompartmental model and a noncompartmental model were applied to the data to obtain the PK results. For both types of administration and both dosages, the ratios of the maximum concentration (Cmax)/MIC50 and the area under the plasma concentration-time curve (AUC)/MIC50 achieved were considerably lower than the fluoroquinolone breakpoints usually adopted for efficacy. The Cmax/MIC50 and AUC0–24/MIC50 ratios were, respectively, 0.67 ± 0.09 and 4.76 ± 0.48 and 1.18 ± 0.35 and 7.05 ± 2.40 for the 15 and 30 mg/kg bolus doses, respectively. After 10-h pulsed administration of 15 mg/kg, values of Cmax/MIC50, 0.19 ± 0.02 on d 1 and 0.30 ± 0.08 on d 5 of therapy were obtained, the AUC/MIC50 ratios were 2.09 ± 0.29 and 3.22 ± 0.93 on d 1 and 5, respectively. Higher values were obtained with the doubled dose of 30 mg/kg: the Cmax/MIC50 ratios were 0.49 ± 0.11 on d 1 and 0.69 ± 0.18 on d 5; the AUC/MIC50 ratios were 5.15 ± 1.15 and 6.57 ± 1.92 on d 1 and 5, respectively. Based on these results, FLU administration should be adopted when specific diagnostic findings indicate its efficacy, and revising the dosage scheme to comply with the prudent and responsible use of antimicrobials in veterinary medicine is advisable

Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study

: Docetaxel has proven effective in advanced breast cancer. Myelosuppression and cumulative fluid retention syndrome are troublesome, potentially avoidable toxicities. In this consecutive cohort study, docetaxel (100 mg/m2 by 1 hour i.v. infusion, q3 weeks) activity and toxicity was explored in 56 anthracycline-pretreated patients (eligible: 55: median age: 51 years [range: 28-68 years]; median performance status: 0 [range: 0-3]) with metastatic breast cancer, using two different granulocyte colony-stimulating factor and steroid pre- and postmedication schedules. Twenty-nine patients (group A) received a 5-day oral prednisone premedication, and 26 (group B) received 4-day low-dose i.m. dexamethasone; group B patients also received prophylactic granulocyte colony-stimulating factor. All patients were evaluable for toxicity and 53 for response. Prophylactic granulocyte colony-stimulating factor significantly lowered the incidence of grade III-IV neutropenia and neutropenic fever (p = 0.0001 and 0.01, respectively). The incidence of moderate-severe fluid retention syndrome was lower in patients receiving i.m. dexamethasone (p = 0.08). Overall response rate was 53% (4 complete responses/24 partial responses, 95% confidence interval 39.4-66.2%); 32% have stable disease and 15% progressive disease. In 21 anthracycline-refractory/resistant patients, as well as in 10 paclitaxel-pretreated patients, the overall response rate was 50%. Docetaxel is highly active in anthracycline- and paclitaxel-pretreated metastatic breast cancer, with manageable toxicity. Optimal use of both granulocyte colony-stimulating factor support and steroid premedication deserves further investigation

Programa de gerenciamento de resíduos de laboratório e campos experimentais na Embrapa Arroz e Feijão.

O objetivo deste trabalho é apresentar o programa de gerenciamento de resíduos de laboratórios e campos experimentais que está sendo implementado na Embrapa Arroz e Feijão.bitstream/CNPAF/25053/1/doc_186.pd